RT Journal Article T1 Real-world biologics response and super-response in the International Severe Asthma Registry cohort A1 Denton, Eve A1 Hew, Mark A1 Peters, Matthew J A1 Upham, John W A1 Bulathsinhala, Lakmini A1 Tran, Trung N A1 Martin, Neil A1 Bergeron, Celine A1 Al-Ahmad, Mona A1 Altraja, Alan A1 Larenas-Linnemann, Désirée A1 Murray, Ruth A1 Celis-Preciado, Carlos Andrés A1 Al-Lehebi, Riyad A1 Belhassen, Manon A1 Bhutani, Mohit A1 Bosnic-Anticevich, Sinthia Z A1 Bourdin, Arnaud A1 Brusselle, Guy G. A1 Busby, John A1 Canonica, Giorgio Walter A1 Heffler, Enrico A1 Chapman, Kenneth R A1 Charriot, Jérémy A1 Christoff, George C A1 Chung, Li Ping A1 García-Cosío, Borja A1 Côté, Andréanne A1 Costello, Richard W. A1 Cushen, Breda A1 Fingleton, James A1 Fonseca, João A A1 Gibson, Peter G A1 Heaney, Liam G A1 Huang, Erick Wan-Chun A1 Iwanaga, Takashi A1 Jackson, David J A1 Koh, Mariko Siyue A1 Lehtimäki, Lauri A1 Máspero, Jorge A1 Mahboub, Bassam A1 Menzies-Gow, Andrew N A1 Mitchell, Patrick D A1 Papadopoulos, Nikolaos G A1 Papaioannou, Andriana I A1 Perez-de-Llano, Luis A1 Perng, Diahn-Warng A1 Pfeffer, Paul E A1 Popov, Todor A A1 Porsbjerg, Celeste M A1 Rhee, Chin Kook A1 Roche, Nicolas A1 Sadatsafavi, Mohsen A1 Salvi, Sundeep A1 Schmid, Johannes M. A1 Sheu, Chau-Chyun A1 Sirena, Concetta A1 Torres-Duque, Carlos A A1 Salameh, Laila A1 Patel, Pujan H A1 Ulrik, Charlotte Suppli A1 Wang, Eileen A1 Wechsler, Michael E A1 Price, David B AB Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real-world population of adults with severe asthma.Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow-up were grouped into those who did, or did not, initiate biologics (anti-IgE, anti-IL5/IL5R, anti-IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV1) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super-response criteria were: FEV1 increase by ≥500 mL, new well-controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day.5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non-initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super-responses. Responses/super-responses were more frequent in biologic initiators than in non-initiators; nevertheless, ~40-50% of initiators did not meet response criteria.Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non-initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super-responses in all outcome domains, 40-50% did not meet the response criteria. YR 2024 FD 2024-06-22 LK https://hdl.handle.net/20.500.13003/20643 UL https://hdl.handle.net/20.500.13003/20643 LA eng NO Denton E, Hew M, Peters MJ, Upham JW, Bulathsinhala L, Tran TN, et al. Real-world biologics response and super-response in the International Severe Asthma Registry cohort. Allergy. 2024 Jun 22. DS Docusalut RD 19 nov. 2026